1. Home
  2. BENF vs ANL Comparison

BENF vs ANL Comparison

Compare BENF & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beneficient

BENF

Beneficient

HOLD

Current Price

$7.08

Market Cap

64.3M

Sector

Finance

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$1.58

Market Cap

52.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BENF
ANL
Founded
2003
2004
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Blank Checks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
64.3M
52.0M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
BENF
ANL
Price
$7.08
$1.58
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
216.7K
31.3K
Earning Date
11-14-2025
04-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$28.85
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.75
$0.88
52 Week High
$12.48
$2.99

Technical Indicators

Market Signals
Indicator
BENF
ANL
Relative Strength Index (RSI) 89.64 49.96
Support Level $3.31 $1.42
Resistance Level $7.21 $1.70
Average True Range (ATR) 0.86 0.18
MACD 0.60 0.04
Stochastic Oscillator 90.58 65.39

Price Performance

Historical Comparison
BENF
ANL

About BENF Beneficient

Beneficient is a technology-enabled financial services holding company that (together with its subsidiaries) provides simple, rapid, and cost-effective liquidity solutions to participants in the alternative asset industry through its end-to-end online platform, AltAccess. BCG's products and services are designed to meet the unmet needs of mid-to-high net-worth individual investors, small-to-midsize institutional investors, family offices, and fund general partners. Its bespoke liquidity solutions for otherwise illiquid alternative asset investments are delivered through proprietary technology and a financing and trust structure. It has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Share on Social Networks: